Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

Sriphoosanaphan, Supachaya; Thanapirom, Kessarin; Suksawatamnuay, Sirinporn; Thaimai, Panarat; Sittisomwong, Sukanya; Sonsiri, Kanokwan; Srisoonthorn, Nunthiya; Teeratorn, Nicha; Tanpowpong, Nattaporn; Chaopathomkul, Bundit; Treeprasertsuk, Sombat; Poovorawan, Yong; Komolmit, Piyawat

doi:10.1186/s12876-020-01485-8

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The curative treatment determines a reduced inflammation-fibrosis and a consequent improvement of hepatic function within a few months [ 46 ]. This amelioration of hepatic status might positively influence vitamin D synthesis, with a slow but progressive increase in serum vitamin D levels [ 47 ]. Before the DAAs-era, HCV therapy was based on IFN: various meta-analyses have demonstrated a better virological response in HCV-positive patients with high serum levels of vitamin D [ 48 ], but contradictory results have been found in the role of vitamin D supplementation on the virological response and the degree of liver fibrosis [ 45 , 49 ].…”

Section: Vitamin D In the Chronic Liver Diseasesmentioning

confidence: 99%

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

Ravaioli

Pivetti

Marco

et al. 2022

IJMS

View full text Add to dashboard Cite

Vitamin D is a crucial nutrient with many pleiotropic effects on health and various chronic diseases. The purpose of this review is to provide a detailed report on the pathophysiological mechanisms underlying vitamin D deficiency in patients with chronic liver disease, addressing the different liver etiologies and the condition of advanced chronic liver disease (cirrhosis) with related complications. To date, patients with liver disease, regardless of underlying etiology, have been shown to have reduced levels of vitamin D. There is also evidence of the predictive role of vitamin D values in complications and progression of advanced disease. However, specific indications of vitamin D supplementation are not conclusive concerning what is already recommended in the general population. Future studies should make an effort to unify and validate the role of vitamin D supplementation in chronic liver disease.

show abstract

Section: Vitamin D In the Chronic Liver Diseasesmentioning

confidence: 99%

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

Ravaioli

Pivetti

Marco

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…В ретроспективном когортном исследовании, включавшем 143 пациентов с хронической HCV-инфекцией (80 с хроническим ВГ и 63 -с ЦП) преимущественно генотипа 1, после достижения УВО на фоне противовирусных препаратов прямого действия средние значения измеренных при ТрЭлГ показателей жёсткости печени спустя 48 нед лечения снизились с 19,2 ± 15,3 до 11,7 ± 8,0 кПа (р < 0,001), а уровни сывороточного биомаркёра N-концевого пропептида проколлагена III типа (PIIINP) через 24 и 48 нед лечения -с 43,6 ± 22,0 до 35,7 ± 21,1 нг/мл и до 29,4 ± 15,0 нг/мл соответственно (р < 0,001) [32].…”

Section: Hсv-ассоциированный цирроз печениunclassified

The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection

Garbuzenko

2021

Problems of Virology

View full text Add to dashboard Cite

The formation of the liver cirrhosis (LC) is an unfavorable event of the natural history of chronic liver diseases being accompanied by complications that often cause a fatal outcome. The study of the effectiveness of drugs that affect various etiopathogenetic mechanisms of this condition is an urgent problem of modern hepatology.The aim of the review was to show the role of antiviral therapy (AVT) in the management of patients with LC associated with chronic HBV (hepatitis B virus) and HCV (hepatitis C virus) infection.PubMed database, Google Scholar search engine, Cochrane Systematic Reviews, eLIBRARY.RU electronic scientific library, as well as the reference lists of articles were used to search for scientific articles. The relevant objectives of the review of the publications were identified for the period since 2000 up to 2021 by the search queries as following: «liver cirrhosis», «liver fibrosis», «chronic HBV infection», «chronic HCV infection», «portal hypertension», «treatment». The inclusion criteria were restricted to the management of patients with LC associated with chronic HBV and HCV infection.Current guidelines recommend indefinite treatment of patients with HBV-associated LC with nucleos(t)ide analogues regardless of serum HBV DNA levels, while the modern concept of using direct-acting antiviral drug combinations has become the standard treatment for HCV-associated cirrhosis. Studies have shown the ability of AVT to inhibit and reverse fibrotic processes in LC associated with chronic HBV and HCV infection. It has also been reported that HBV/HCV eradication prior to orthotopic liver transplantation improves long-term overall survival.This, in turn, can reduce the severity of portal hypertension and decrease the risk of associated complications, as well as normalize liver function. Thus, ensuring the availability of drugs for those in need of AVT will not only help prevent the development of LC, but also improve the quality of life and increase its expectancy of patients suffering from this disease.

show abstract

“…Low serum VD levels could lead to negative liver-related consequences and liver fibrosis progression (Dadabhai et al, 2017;Kubesch et al, 2018). Moreover, in a recent clinical study, since the liver is an intermediate organ of VD metabolism, a high proportion of patients with CHC still have VD deficiency and insufficiency after successful HCV eradication (Backstedt et al, 2017;Sriphoosanaphan et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial

Sriphoosanaphan

Thanapirom

Kerr

et al. 2021

PeerJ

Self Cite

View full text Add to dashboard Cite

Background Replacement of vitamin D (VD) among patients with chronic hepatitis C (CHC) before viral eradication has demonstrated a protective effect on serum markers associated with hepatic fibrogenesis. We therefore hypothesized that VD may facilitate further fibrosis amelioration following curative treatment with direct-acting antivirals (DAA). Methods This study was a randomized, double-blind, placebo-controlled trial conducted between February 2018 and August 2018. Patients with CHC and VD deficiency were randomized in a 1:1 ratio to either receive ergicalciferol or placebo over 6 weeks. Biochemical analysis indicators, including 25-hydroxyvitamin D (25(OH)D), fibrogenic markers [(transforming growth factor beta 1 (TGF-β1) and tissue inhibitors of matrix metalloproteinases 1 (TIMP-1)], and fibrolytic markers [matrix metalloproteinase 9 (MMP-9) and amino terminal type III procollagen peptide (P3NP)], were assessed at baseline and at 6 weeks. Serum 25(OH)D was analyzed by a chemiluminescence immunoassay. Serum hepatic fibrogenesis markers were measured using a quantitative sandwich enzyme-linked immunosorbent assay. Results Seventy-five patients with CHC and VD deficiency were randomly assigned to VD (n = 37) and placebo (n = 38) groups. At the end of the study, the mean serum 25(OH)D level had risen to a normal level in the VD group, but was still deficient in the placebo group (41.8 ± 9.1 vs. 18.1 ± 4.6 ng/mL, p < 0.001). Upon restoration of the VD level, there were no significant mean differences in the change from baseline for TGF-β1 (−0.6 ng/mL (95% confidence interval (95% CI) [−2.8–1.7]), p = 0.63), TIMP-1 (−5.5 ng/mL (95% CI [−26.4 –15.3]), p = 0.60), MMP-9 (122.9 ng/mL (95% CI [−69.0 –314.8]), p = 0.21), and P3NP (−0.1 ng/mL (95% CI [−2.4 –2.2]), p = 0.92) between the VD and placebo groups. Conclusion Short-term VD supplementation after DAA treatment in patients with CHC does not improve serum fibrogenesis markers and may not expedite the residual liver fibrosis healing process. Future studies are warranted to evaluate the long-term effect of VD supplementation on hepatic fibrosis regression.

show abstract

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

Cited by 3 publications

References 36 publications

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection

Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About